Alkem Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Alkem Laboratories announced the incorporation of a wholly owned subsidiary in the name of Alkem Pharma Trading FZCO in Dubai, UAE. The subsidiary will undertake export of company's products to African, South East Asian and non-UAE markets.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5428.5, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.99% on the day, quoting at 24011.35. The Sensex is at 77413.31, up 1.02%. Alkem Laboratories Ltd has slipped around 2.09% in last one month.

Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 5.16% in last one month and is currently quoting at 22135.4, up 0.04% on the day. The volume in the stock stood at 34997 shares today, compared to the daily average of 1.27 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 5438.5, up 0.72% on the day. Alkem Laboratories Ltd is up 11.07% in last one year as compared to a 5.18% spurt in NIFTY and a 8.22% spurt in the Nifty Pharma index.

The PE of the stock is 29 based on TTM earnings ending December 25.

 Alkem Laboratories announced the launch of A to Z Daily, an everyday multivitamin supplement for adults, for providing holistic nutritional support to the body and mind.

A to Z Daily tablets are formulated with a total of 26 essential vitamins, minerals and botanicals to provide balanced nutritional support. The key vitamins and minerals include Vitamin B complex, Vitamin D3, Vitamin C, Zinc, and Iron that help in boosting energy levels, reducing fatigue and improving immunity. The product also contains clinically researched botanicals such as Ashwagandha, Bacopa monnieri (Brahmi), Panax ginseng, and an amino acid L-theanine, which help in managing stress and anxiety, improving sleep quality and supporting the cognitive function.

Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, ?Our current lifestyles are placing sustained demands not just on physical health but also on mental well-being. People are increasingly experiencing stress, fatigue, and reduced ability to stay focused. Nutritional supplementation can play a supportive role in addressing these challenges when designed thoughtfully. A to Z Daily brings together essential ingredients to provide a balanced, everyday support for both body and mind. It is positioned not as a quick fix, but as a consistent, long-term approach for people seeking to manage everyday stress while improving overall vitality.?

The certificate is valid for a period of three years from the date of inspection being 09th December, 2025.

The inspection was conducted between 5 December 2025 and 9 December 2025. Following the inspection the facility was granted the GMP compliance certificate, subject to three major observations along with a few minor observations noted by the authority.

Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.

The company?s consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY25. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025.

The scrip rose 0.32% to end at Rs 5,257.75 on the BSE.

Powered by Capital Market - Live News